In January, the U-M Michigan Translational Research and Commercialization for Life Sciences Program (U-M MTRAC) reviewed 17 funding proposals for innovative technologies; 11 were selected for funding, three of which are headed by MCIRCC Members Kevin Ward, MD; Albert Shih, PhD; Anna Schwendeman, PhD; Mohamad Tiba, MD; and James Blum, MD.
Principal investigators presented on proof-of-concept projects previously reported to the Office of Technology Transfer. Projects evaluated to have a high potential for translation into the commercial industry were selected for funding by an Oversight Committing comprised of global biotech business experts and U-M leaders in translational science and technology transfer. Funding can go towards project expenditures such as salary and fringe benefits for project personnel, materials and supplies, equipment and travel.
The proposals covered technology ranging from a fluorescently labeled peptide to be used for early detection for colorectal cancer to a novel, continuous, non-invasive method of monitoring patient volume status. Of the 11 projects selected for funding by the MTRAC Oversight Committee, the following highlights the three MCIRCC Member projects:
SRB-1 targeted with anolide nanoconjugates for improved targeted therapy of endocrine cancers developed by Anna Schwendeman, PhD (and Dr. Mark Cohan).
An integral part of the Medical School's Strategic Research Initiative and its Fast Forward Medical Innovation program, U-M MTRAC for Life Sciences has over $7.5 million dollars to be used over the course of three years to accelerate U-M's biomedical innovation pipeline. For more information contact Brad Martin, Commercialization Program Director.
MCIRCC’s primary goal is to integrate disciplines and push research beyond the idea stage to bring innovative technologies to market for real-world impact. As such, MCIRCC recognizes and values the work done by all PI’s and would like to congratulate each awardee for their hard work and dedication.